SureTrader
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

Nice, James. The cost of NEO and other

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ignatiusrielly35 Member Profile
Member Level 
Followed By 10
Posts 4,515
Boards Moderated 0
Alias Born 11/18/16
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2018 5:29:09 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 5:33:13 PM
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of M... Business Wire - 2/13/2018 8:30:00 AM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic ... Business Wire - 2/12/2018 9:15:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/6/2018 5:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2018 5:04:42 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen... Business Wire - 1/29/2018 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/25/2018 5:04:55 PM
Traders News Source Issues Stocks on Watch and a New Feature Report InvestorsHub NewsWire - 1/25/2018 8:05:00 AM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in Internation... Business Wire - 1/25/2018 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/9/2018 5:18:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:02:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:01:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/21/2017 6:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 4:21:23 PM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire - 12/20/2017 4:15:00 PM
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire (US) - 12/20/2017 8:05:00 AM
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire - 12/14/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:35:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:31:53 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma PR Newswire (US) - 11/27/2017 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 11/9/2017 5:25:39 PM
ignatiusrielly35 Member Level  Friday, 10/06/17 08:52:23 AM
Re: James salmon post# 37330
Post # of 55534 
Nice, James. The cost of NEO and other personalized treatments also implies that there is room in the market for the "base" treatments such as AXAL, PSA, HOT, etc., even if NEO succeeds. Especially in the large markets like China and India.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist